Prime Medicine, a preclinical biotech developing novel gene editing therapies for various diseases, filed on Friday with the SEC to raise up to an estimated $200 million in an initial public offering.
The company is developing one-time curative genetic therapies, and currently has 18 preclinical programs targeting areas such as sickle cell disease, various liver diseases, non-syndromic hearing loss, neuro-muscular conditions, Duchenne muscular dystrophy, and cystic fibrosis. Prime Medicine has established preclinical proof-of-concept in vivo with long term engraftment of edited human cells in mice targeting sickle cell disease.
The Cambridge, MA-based company was founded in 2019 and plans to list on the Nasdaq under the symbol PRME. Prime Medicine filed confidentially on December 20, 2021. J.P. Morgan, Goldman Sachs, Morgan Stanley, and Jefferies are the joint bookrunners on the deal. No pricing terms were disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.